LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Zimmer Settles Employee Misclassification Class Action for $7.3M
Legal & Regulatory and Reimbursement

Zimmer Settles Employee Misclassification Class Action for $7.3M

August 6, 2021 2 min read Premium comments

Advertisement

#zimmerbiometSecondary#classaction#independentcontractors

The United States District Court for the Northern District of California has issued an order granting preliminary approval of a class settlement agreement between a class of independent contractors and Zimmer Biomet Holdings, Inc. and its subsidiaries.

The lawsuit originated when a California sales associate sued Zimmer U.S., Inc., Biomet U.S. Reconstruction, LLC, and Biomet Biologics, LLC. Per the plaintiff’s motion for preliminary approval of amended class action settlement agreement, the sales associate alleged that the companies “unlawfully misclassified California sales representatives as independent contractors.”

The plaintiff’s relationship with Zimmer began when he began selling orthopedic devices to physicians and hospitals in San Francisco, California. Per his sales associate agreement with Zimmer, the plaintiff was classified as an independent contractor. As an independent contractor, he was a member of a sales team in his region and his team was paid on a commission-only “pooled” arrangement.

In order to resolve the matter, the parties engaged in settlement conferences and were able to negotiate a settlement agreement. Per the order granting preliminary settlement approval, “the proposed settlement creates a $7,380,482.10 fund to compensate a class of approximately 246 members.”

The proposed settlement will be distributed to the class members on a “pro-rata basis based upon bi-weekly service pay periods.” The fund will provide “approximately $336 per bi-weekly pay period or $672 per month.” This amount may pale in comparison to Zimmer’s actual potential exposure if the lawsuit proceeded. The plaintiff asserts that the settlement “represents approximately 15.31% of Zimmer’s total exposure in this suit—estimated at $48,196,516.”

In addition to the settlement fund, “class members currently contracting with Zimmer will also be offered full employment as IRS form W-2 employees.” Reclassification will entitle the employees to rights and protections under California law that are not available to independent contractors.

While the court preliminarily approved the settlement agreement, the order granting preliminary settlement approval called for two revisions to the employee reclassification section. The first revision requires that the reclassification section “alert class members that reclassification is limited to those who have satisfactory job performance, and, if they have not satisfactorily performed their job, they will be terminated.” The second revision requires that “sales representatives that make above $300,000 have the option of retaining their status as independent contractors.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy